Akamis Bio

London, United Kingdom · Founded 2020 · $90.0M raised

Headquarters
London
Employees
11–50
Founded
2020
Business Model
B2B
Total Funding
$90.0M
Last Round
$60.0M Series ADec 2024
Rounds
2

About

Akamis Bio is developing oncolytic immunotherapies to expand treatment options for people living with colorectal cancer. The company aims to create medicines that can directly attack a patient's tumor while potentially reducing the need for surgical interventions, helping patients preserve colorectal function and improve their quality of life. A team of scientists, clinicians, and innovators, Akamis Bio is working to transform the standard of care for colorectal cancer through its oncolytic immunotherapy programs.

Summary

Akamis Bio is a Biotech company based in London, United Kingdom, founded in 2020. It has raised $90.0M in total across 2 rounds, most recently a $60.0M Series A round in Dec 2024. Investors include Sedgwick Yard, ARCH Venture Partners and Parker Institute for Cancer Immunotherapy.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries ADec 2024
$60.0M

Sign up to see all 2 rounds

Convertible Note through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Akamis Bio on Indexed.vc
<a href="https://indexed.vc/companies/akamis-bio"><img src="https://indexed.vc/api/badge/company/akamis-bio" alt="Akamis Bio on Indexed.vc" width="260" height="76" /></a>